ISPOR EU 2024
Comparison of the guidelines for quantitative evidence synthesis in the European Union (EU) joint clinical assessment (JCA) of medicinal products to current methods for health technology assessment (HTA) in Germany
Martina Maier, Christina Meier, Marie Becker, Caroline Scheulen, Julia Specks, Marie Hinnenthal, Katrin Blondrath, Alexander Rich, Magdalena Oberhauser, Penelope Gallinger, Doreen Bonduelle, Anke van Engen
Link
Comparison of the joint clinical assessment (JCA) dossier with the German Medicines Market Reorganization Act (AMNOG) dossier – what content remains to be presented in the AMNOG dossier after implementation of JCA?
Marie Becker, Martina Maier, Isabel Ernst, Denise Böckmann, Maximilian Rauch, Magdalena Oberhauser, Penelope Gallinger, Doreen Bonduelle, Anke van Engen
Link
EU joint clinical assessment (JCA): Uncertain impact on German AMNOG timelines and potential delays
Janika Drews, Martina Maier, Edel Falla, Anke van Engen, Penelope Gallinger
Link
Could the European joint clinical assessment (EU JCA) delay access to new medicines in France?
Dima Samaha, Valentine Berthet, Lise Amoura, Marine Olive
Link
From clinical assessment to drug reimbursement in Spain: Current timelines and potential impact from the joint clinical assessment
Mafalda Carmo, Pablo Encina, Marco Pinel, Daniel Callejo-Velasco
Link
Potential impact of joint clinical assessment (JCA) on health technology assessment timelines in Ireland
Michael McCarthy, Edel Falla
Link
When timelines collide: How EMA regulatory milestones can impact the JCA process, and implications for manufacturers and member states
Dan Newsome, William Fox, Edel Falla, Anke van Engen
Link
The butterfly effect: Impact of EU HTA on price evolution via international reference pricing
Sian Tanner, Rebecca Coady, Benedetta Spadaro, Giorgio Karapetsas, Anke van Engen
Link
A blueprint for success: The importance of multi-stakeholder alignment for EU health technology assessment (HTA)
Aikaterini Fameli, Sally Chung, Sian Tanner, Thomas Paulsson, Indranil Bagchi
Link
Indirect treatment comparisons with full individual patient data for joint clinical assessment: Lessons learned and best practices from a review of HTA appraisals
Max Schlueter, George Nikolaidis, Robert Krüger
Link
Predicting PICOs to prepare for joint clinical assessment – learnings from 19 case studies
Anke van Engen, Edel Falla, Corinna Oswald, Paula Szawara, Ana Lisica, Robert Krüger, Dan Newsome, Sian Tanner, Benedetta Spadaro, Jess Walters, Anastasia Stamoulou, João Leite, Ansa Ibok, Fani Kotseva, Alexandre Quequet-Leyssieux, Oliver Curtis, Anna Kullnigg, Xenia Sitavu-Radu, Lise Amoura
Link
Vaccines and EU HTA: Exploring misalignments between joint clinical assessment requirements and a hypothetical vaccine evidence package
Sian Tanner, Dorothee Mugele, Rebecca Coady, Pascaline Faivre, Anke van Engen
Link
A comparison of the acceptability of evidence in the new joint clinical assessment and nine European Union countries
Veronique Lambert, Bhakti Arondekar, Justin Doan, Savvas Dimiou, Ana Lisica, Corinna Oswald, Edel Falla, Sarah Karchere
Link
Predicting the evidence requirement implications of the European Union (EU) joint clinical assessment (JCA) by conducting a Population, Comparator, Intervention, Outcome (PICO) simulation for two anticancer investigational medicinal products (IMPs)
Eirini Anastasaki, Nicolas Despiegel, Franziska Dirnberger, Anke van Engen, Istvan Majer, Corinna Oswald, Paula Szawara, Rumbi Takundwa, Sunny Ubi
Link
The horizon of oncology: Estimating the impact of new EU Regulation on health technology assessment for 2025-2028
Laura Candelora, Margherita Marchetto, Gloria Lombardi, Michele Caimmi, Paola La Malfa, Duccio Urbinati
Link
Including patient experience data in the HTA decision-making framework: A proposal based on HTA-stakeholder interviews
Isa Hemmer, Marieke Krol
Link
Use of artificial intelligence and machine learning (AI/ML) in systematic literature reviews (SLR): Review of state-of-the-art health technology assessment and future directions
Ketevan Rtveladze, Theodora Oikonomidi, Nermina Ferizovic, Kalyan Pulleddula, Bala Ganesh Geddamuri, P Agrawal, Tanushree Chaudhary
Link
Do we need to adapt our health technology assessment (HTA) systematic literature review (SLR) methods to comply with the new Joint Clinical Assessment (JCA) SLR?
Theodora Oikonomidi, Tanushree Chaudhary, Sheily Kamra, Kalyan Pulleddula, Bala Ganesh Geddamuri, P Agrawal, Jennifer Gaultney, Ketevan Rtveladze
Link